Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer

被引：0
|
作者：
Kim, C. [1 ]
Xi, L. [2 ]
Cultraro, C. [1 ]
Pham, T. [2 ]
Roper, N. [1 ]
Bagheri, M. [3 ]
Rajan, A. [1 ]
Beeler, J. [4 ]
Jones, G. [4 ]
Raffeld, M. [2 ]
Guha, U. [1 ]
机构：
[1] NCI, Thorac & Gastrointestinal Oncol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] NIH, Radiol & Imaging Sci Dept, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA
[4] Inivata Inc, Res Triangle Pk, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
EGFR-mutant NSCLC; osimertinib; Circulating Tumor DNA;
D O I：
10.1016/j.jtho.2018.08.602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-46
引用
收藏
页码：S478 / S478
页数：1
相关论文
共 50 条
  • [1] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    [J]. CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [2] Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
    Kim, Chul
    Xi, Liqiang
    Cultraro, Constance M.
    Wei, Fang
    Jones, Gregory
    Cheng, Jordan
    Shafiei, Ahmad
    Pham, Trinh Hoc-Tran
    Roper, Nitin
    Akoth, Elizabeth
    Ghafoor, Azam
    Misra, Vikram
    Monkash, Nina
    Strom, Charles
    Tu, Michael
    Liao, Wei
    Chia, David
    Morris, Clive
    Steinberg, Seth M.
    Bagheri, Hadi
    Wong, David T. W.
    Raffeld, Mark
    Guha, Udayan
    [J]. CANCERS, 2021, 13 (13)
  • [3] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
    Cai, Xueting
    Miao, Jing
    Sun, Rongwei
    Wang, Sainan
    Molina-Vila, Miguel Angel
    Chaib, Imane
    Rosell, Rafael
    Cao, Peng
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 170
  • [4] Minimal residual disease in EGFR-mutant non-small-cell lung cancer
    Bain, Nathan T. T.
    Wang, Yang
    Arulananda, Surein
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Treatment choice in EGFR-mutant non-small-cell lung cancer
    Brueckl, Wolfgang M.
    [J]. LANCET ONCOLOGY, 2017, 18 (11): : 1425 - 1426
  • [6] Spontaneously expectorated EGFR-mutant non-small-cell lung cancer
    Sumi, Toshiyuki
    Terai, Kotomi
    Chiba, Hirofumi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (11) : 1094 - 1095
  • [7] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    [J]. PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [8] Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non-small-cell lung cancer (TREBLE).
    Johnson, Melissa Lynne
    Miller, Vincent A.
    Patel, Suraj
    Zhao, Yumin
    Cheng, Li
    Ali, Siraj Mahamed
    Wooten, Michael
    Daniel, Davey B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [10] Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment
    Beagan, Jamie J.
    Bach, Sander
    van Boerdonk, Robert A.
    van Dijk, Erik
    Thunnissen, Erik
    van den Broek, Daan
    Weiss, Janneke
    Kazemier, Geert
    Pegtel, D. Michiel
    Bahce, Idris
    Ylstra, Bauke
    Heideman, Danielle A. M.
    [J]. LUNG CANCER, 2020, 145 : 173 - 180
12345